The results from the first randomized, placebo-controlled study for Gilead Sciences Inc.’s remdesivir in China have seemingly disappointed, but some say the repurposed antiviral may still go on to get a regulatory approval for COVID-19.
Originally designed to enroll 237 patients, the study was terminated early due to a lack of participants in Wuhan, the...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

